CA
GNMX

Commerzbank Aktiengesellschaft’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Commerzbank Aktiengesellschaft’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-15,000
Closed -$117K – 1442
2013
Q3 		$117K Sell
15,000
-68,313
-82% -$317K ﹤0.01% 1266
2013
Q2 		$317K Buy
+83,313
New +$341K ﹤0.01% 1221

Other funds holding GNMX

Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Commerzbank Aktiengesellschaft's GNMX Position: Q4 2013 in Review

Commerzbank Aktiengesellschaft sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2013, closing a stake of 15,000 shares — an estimated $117K sold.

Commerzbank Aktiengesellschaft first reported a position in GNMX in Q2 2013 and held it in 2 quarters. The position peaked at $317K in Q2 2013. 26 funds tracked by Wall St. Rank hold GNMX as of Q4 2013.

  • Commerzbank Aktiengesellschaft reported no remaining Aevi Genomic Medicine Inc position as of Q4 2013 after selling out during the quarter.
  • Commerzbank Aktiengesellschaft sold 15,000 Aevi Genomic Medicine Inc shares in Q4 2013, an estimated $117K.
  • Commerzbank Aktiengesellschaft first reported a position in Aevi Genomic Medicine Inc in Q2 2013 and held it in 2 quarters.
  • Commerzbank Aktiengesellschaft's Aevi Genomic Medicine Inc position peaked at $317K in Q2 2013.
  • 26 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2013.

Based on Commerzbank Aktiengesellschaft's 13F filing for Q4 2013, filed 13 Feb 2014.